Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Skyline Therapeutics Develops SKG0106, a Novel Gene Therapy Candidate

Skyline Therapeutics developed SKG0106, a novel intravitreally delivered AAV gene therapy targeting neovascular age-related macular degeneration (nAMD). 

SKG0106 is a distinctively designed recombinant adeno-associated virus (rAAV)-mediated gene therapy for ocular diseases. The therapy includes a proprietary novel AAV capsid, which is the outer shell of the virus, and a uniquely configured transgene genome that encodes the production of an anti-VEGF (vascular endothelial growth factor) protein.

SKG0106 is an investigational gene therapy utilising a proprietary novel recombinant adeno-associated viral vector. The therapy aims to prevent choroidal or retinal neovascularization, relieve retinal oedema, and reduce vascular leakage in patients with nAMD.

The therapy contains a uniquely configured transgene that has shown potent inhibition effects on intraocular neovascularization, making it a promising candidate for the treatment of serious ophthalmic conditions, including neovascular age-related macular degeneration (nAMD).

SKG0106 has undergone robust preclinical proof-of-concept studies, demonstrating its safety and efficacy as an anti-angiogenic treatment with durable suppression of neovascular lesions following a low-dose single intravitreal injection. 

Skyline Therapeutics obtained FDA clearance of the Investigational New Drug (IND) application for SKG0106, a novel intravitreally delivered adeno-associated virus (AAV) gene therapy candidate.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024